NEWS
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform (Nasdaq: PRFX) has announced positive results regarding the compatibility of sutures in human clinical trials for its lead product, PRF-110. The company conducted in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures, specifically PROLENE™ and Vicryl™. The results showed that PRF-110 does not affect the mechanical properties of these sutures, including breaking force and elongation, after 14 days of exposure.
This finding is consistent with the phase III clinical results from the bunionectomy trial and supports the safety and efficacy of PRF-110 in post-surgical pain management. The compatibility of PRF-110 with surgical sutures is a significant advancement in post-operative care, as it allows for extended, non-opiate pain relief without compromising suture integrity.
This finding is consistent with the phase III clinical results from the bunionectomy trial and supports the safety and efficacy of PRF-110 in post-surgical pain management. The compatibility of PRF-110 with surgical sutures is a significant advancement in post-operative care, as it allows for extended, non-opiate pain relief without compromising suture integrity.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2490Followers
107Following
27KVisitors
Follow